Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups. (October 2022)

Record Type:: Journal Article
Title:: Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups. (October 2022)
Main Title:: Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups
Authors:: Gogishvili, M.
Kilickap, S.
Sezer, A.
Gümüş, M.
Bondarenko, I.
Özgüroğlu, M.
He, X.
Gullo, G.
Rietschel, P.
Quek, R.G.W.
Abstract:
Is Part Of:: Journal of geriatric oncology. Volume 13(2022)Supplement 1
Journal:: Journal of geriatric oncology
Issue:: Volume 13(2022)Supplement 1
Issue Display:: Volume 13, Issue 1 (2022)
Year:: 2022
Volume:: 13
Issue:: 1
Issue Sort Value:: 2022-0013-0001-0000
Page Start:: S3
Page End:
Publication Date:: 2022-10
Subjects:: Geriatric oncology -- Periodicals
Neoplasms -- Periodicals
Aged -- Periodicals
Geriatric oncology
Electronic journals
Periodicals
618.976994005
Journal URLs:: http://www.clinicalkey.com.au/dura/browse/journalIssue/18794068 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/18794068 ↗
http://www.sciencedirect.com/science/journal/18794068 ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/S1879-4068(22)00251-X ↗
Languages:: English
ISSNs:: 1879-4068
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 24235.xml